SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
855I think EXEL's MEK partnered with Roche may have relevance to EXEL's primcbio-1/25/2012
854Would be good if someone who knows details about relative efficacy, HCC, commentscaram(o)uche-1/23/2012
853How do you guys evaluate this Press Release? Thanks. Exelixis Reports Positive Malyshek-1/21/2012
852Exelixis Licenses PI3K-Delta Program to MerckExelixis to receive $12M upfront paIRWIN JAMES FRANKEL-12/21/2011
851EXEL Piper Jaffray Health Care Conference Call November 29, 2011 Ted Tenthoff mopgcw-12/17/2011
850Copied off IH: [worth a look] The poster is available on Exelixis website. HerIRWIN JAMES FRANKEL-12/9/2011
849Exelixis' Cabozantinib Shows Encouraging Clinical Activity in Patients With IRWIN JAMES FRANKEL-12/7/2011
848This post from jq1234 (he strikes me as skilled scientifically) on Ihub: silicoIRWIN JAMES FRANKEL-12/2/2011
847Earnie on YM R&D day 1-Dec-11 02:00 pm It was informative. There was moreIRWIN JAMES FRANKEL112/1/2011
846no competition from Revlimid? 4:44PM Celgene will discontinue Phase III MAINSAIIan@SI-11/22/2011
845Exelixis Announces Initiation of Phase 2 Investigator-Sponsored Trial of CabozanIRWIN JAMES FRANKEL-11/21/2011
844Earnie on YM: <<These types of comments usually come from someone who hasIRWIN JAMES FRANKEL-11/17/2011
843Earnie on YM: The only drug with a pain label for CRPC is Mitoxantrone. ProblemIRWIN JAMES FRANKEL-11/17/2011
8426:47PM Amgen reports that a study found XGEVA significantly prolonged bone metaIan@SI-11/15/2011
841EXEL put up a page with links to the posters: exelixis.comIRWIN JAMES FRANKEL-11/14/2011
840Earnie from YM: Differentiated Thyroid Cancer13-Nov-11 04:50 am exelixis.com IRWIN JAMES FRANKEL-11/13/2011
839Earnie from YM: Another look at the SPA13-Nov-11 03:59 am Let's look agaiIRWIN JAMES FRANKEL-11/13/2011
838Earnie from YM: Low dose data13-Nov-11 03:32 am "Twelve patients were enIRWIN JAMES FRANKEL-11/13/2011
837Earnie from YM: Pain data13-Nov-11 02:44 am Alright, let's look at this oIRWIN JAMES FRANKEL-11/13/2011
836From hbomb on YM: ejnmmires.com Preliminary research18F-fluoride PET: changes IRWIN JAMES FRANKEL-11/12/2011
835abstractsonline.com Abstract Number:B114Presentation Title:Cabozantinib effectsIRWIN JAMES FRANKEL-11/12/2011
834abstractsonline.com Abstract Number:C26Presentation Title:A phase 1 multiple asIRWIN JAMES FRANKEL-11/12/2011
833abstractsonline.com Abstract Number:B57Presentation Title: Cabozantinib (XL184IRWIN JAMES FRANKEL-11/12/2011
832abstractsonline.com Abstract Number:A90Presentation Title:Efficacy and TolerabiIRWIN JAMES FRANKEL-11/12/2011
831Exelixis Announces November 15th Webcast of Presentation at the Lazard Capital MIRWIN JAMES FRANKEL-11/10/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News